Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 1,238 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 1,238 shares of Phreesia stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $22.86, for a total value of $28,300.68. Following the completion of the sale, the general counsel now owns 135,621 shares of the company’s stock, valued at $3,100,296.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phreesia Price Performance

NYSE PHR opened at $22.62 on Friday. The business has a 50 day simple moving average of $24.40 and a 200 day simple moving average of $21.26. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $34.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.78 and a quick ratio of 1.78.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.02. The company had revenue of $95.00 million during the quarter, compared to analysts’ expectations of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The business’s quarterly revenue was up 24.0% on a year-over-year basis. During the same period last year, the business earned ($0.72) EPS. As a group, analysts forecast that Phreesia, Inc. will post -1.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research report on Thursday, March 21st. Stephens reaffirmed an “overweight” rating and issued a $28.00 price target on shares of Phreesia in a research note on Friday, March 22nd. Canaccord Genuity Group upped their price target on Phreesia from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Raymond James reaffirmed an “outperform” rating and issued a $30.00 price target (up from $25.00) on shares of Phreesia in a research note on Friday, March 15th. Finally, Barclays initiated coverage on Phreesia in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $29.00 price target for the company. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Phreesia currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.62.

Hedge Funds Weigh In On Phreesia

Hedge funds have recently made changes to their positions in the business. CI Investments Inc. grew its stake in shares of Phreesia by 6.6% during the 3rd quarter. CI Investments Inc. now owns 477,265 shares of the company’s stock worth $8,915,000 after acquiring an additional 29,500 shares in the last quarter. Schroder Investment Management Group bought a new position in shares of Phreesia during the 3rd quarter worth approximately $6,514,000. TimesSquare Capital Management LLC boosted its holdings in shares of Phreesia by 7.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company’s stock valued at $14,460,000 after buying an additional 55,793 shares during the last quarter. Trust Point Inc. acquired a new stake in shares of Phreesia in the 4th quarter valued at approximately $239,000. Finally, Lazard Asset Management LLC boosted its holdings in shares of Phreesia by 58.6% in the 3rd quarter. Lazard Asset Management LLC now owns 424,047 shares of the company’s stock valued at $7,921,000 after buying an additional 156,711 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.